Diabetic macular edema (DME) is the leading cause of moderate vision loss in diabetics. Modalities to image and monitor DME have evolved much in the last decade. Systemic control is the most important part of management. Available ocular management options include intravitreal antivascular endothelial growth factor (anti-VEGF) agents, laser, steroids (intravitreal or peribulbar), vitrectomy, topical medications and others. Anti-VEGF agents are increasingly being used in clinical practice with good clinical response and are currently the preferred mode of treatment worldwide.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/1573399811999150324120640 | DOI Listing |
Noise Health
January 2025
Department of Ophthalmology, Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian, China.
Background: With the aging of the population, the deterioration of visual and auditory functions amongst the elderly has attracted much attention. Age-related hearing loss (ARHL) and age-related macular degeneration (AMD) are common eye and ear diseases that seriously affect the quality of life of elderly population.
Methods: This study utilised a whole cohort sampling method, with a total of 713 participants aged 50 years and older in the community from June 2022 to October 2023, resulting in the inclusion of 620 participants.
Retina
January 2025
Ophthalmology Clinic, Department of Biomedical Sciences, University of Messina, Italy.
Purpose: This literature review synthetizes current evidence on the timing and efficacy of dexamethasone intravitreal injections for diabetic macular edema (DME) in patients undergoing cataract surgery, particularly phacoemulsification, to determine the optimal timing for improved outcome.
Methods: A systematic review of the literature was conducted across key databases to identify peer-reviewed studies, clinical trials, and meta-analyses addressing dexamethasone injections administered pre-, intra-, and post-operatively for DME in the context of cataract surgery. Studies were selected based on relevance to timing, visual outcomes, and inflammation control, with a focus on comparative efficacy.
Transl Vis Sci Technol
December 2024
Department of Ophthalmology, Kyung Hee University Medical Center, Kyung Hee University, Seoul, Korea.
Purpose: To evaluate changes in the retinal microvasculature using widefield swept-source optical coherence tomography angiography (SS-OCTA) following three anti-vascular endothelial growth factor (anti-VEGF) loading injections for diabetic macular edema (DME).
Methods: Thirty-four treatment-naïve patients with DME received an initial three loading injections, followed by injections on an as-needed basis. Macular ischemia was evaluated based on the foveal avascular zone (FAZ) area, perfusion density, and vessel density on a 3 × 3-mm SS-OCTA image.
Alzheimers Dement
December 2024
West China Hospital of Sichuan University, Chengdu, China.
Background: Alzheimer's disease (AD) and Frontotemporal dementia (FTD) are the two most common causes of early-onset dementia. Differentiating between AD and FTD can be challenging due to overlapping cognitive and behavioral manifestations. However, evidence on non-invasive and early-stage biomarkers for differentiating AD and FTD is still limited.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Ophthalmology, University of Washington, Seattle, WA, USA.
Background: To describe the settings and compare demographic and baseline clinical factors of the inaugural Eye Adult Changes in Thought (ACT) study participants.
Method: Adult Changes in Thought (ACT) is an ongoing cohort study of older adults (≥ 65 years) randomly recruited from Kaiser Permanente Washington who were cognitively normal at enrollment and followed biennially for the onset of Alzheimer's disease since 1994. Cognitive testing included the Cognitive Abilities Screening Instrument scored using Item Response Theory (CASI-IRT) with other measures of cognition.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!